Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fluzoparib + Famitinib maintenance after first-line platinum chemotherapy in HRD-negative advanced ovarian cancer
ChiCTR2600124533Phase 2Not yet recruiting
- Sponsor
- Yantai Yuhuangding Hospital
- Start
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of fluzoparib and famitinib in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC), sponsored by Yantai Yuhuangding Hospital. Primary endpoint: Progression-Free Survival (PFS) assessed by investigators. Planned start May 2026; status: not yet recruiting.
02
Drugs
fluzoparibfamitinib
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on ChiCTR2600124533.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600124533.